Prime Medicine, Inc. (PRME) Revenue History
Annual and quarterly revenue from 2019 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
PRME Revenue Growth
Revenue Breakdown (FY 2025)
PRME's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
PRME Revenue Analysis (2019–2025)
As of May 6, 2026, Prime Medicine, Inc. (PRME) generated trailing twelve-month (TTM) revenue of $4.6 million, reflecting significant decline in growth of -61.6% year-over-year. The most recent quarter (Q4 2025) recorded $838,000 in revenue, down 31.6% sequentially.
Looking at the longer-term picture, PRME's 5-year compound annual growth rate (CAGR) stands at -2.3%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $5.2 million in 2020.
Revenue diversification analysis shows PRME's business is primarily driven by Reportable Segment (100%). With over half of revenue concentrated in Reportable Segment, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including BEAM (+120.0% YoY), CRSP (-88.9% YoY), and KRRO (+181.5% YoY), PRME has underperformed the peer group in terms of revenue growth. Compare PRME vs BEAM →
PRME Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| PRMECurrent | $5M | -61.6% | -2.3% | -4498.1% | |
 BEAM | $140M | +120.0% | +466.3% | -274.6% | |
 CRSP | $4M | -88.9% | +37.3% | -16191.4% | |
 KRRO | $6M | +181.5% | -29.6% | -1366.4% |
PRME Historical Revenue Data (2019–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $4.6M | +55.3% | $-2,689,000 | -58.1% | $-208,350,000 | -4498.1% |
| 2024 | $3.0M | - | $3.0M | 100.0% | $-202,467,000 | -6787.4% |
| 2023 | $0 | - | $0 | - | $-204,792,000 | - |
| 2022 | $0 | - | $0 | - | $-116,544,000 | - |
| 2021 | $0 | -100.0% | $0 | - | $-84,474,000 | - |
| 2020 | $5.2M | - | $2.2M | 42.8% | $-932,000 | -17.9% |
| 2019 | $0 | - | $-2,760,000 | - | $-2,172,000 | - |
See PRME's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PRME Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PRME vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPRME — Frequently Asked Questions
Quick answers to the most common questions about buying PRME stock.
Is PRME's revenue growth accelerating or slowing?
PRME revenue declined -61.6% year-over-year, contrasting with the 5-year CAGR of -2.3%. TTM revenue fell to $5M. This reverses the prior growth trend.
What is PRME's long-term revenue growth rate?
Prime Medicine, Inc.'s 5-year revenue CAGR of -2.3% reflects the variable expansion pattern. Current YoY growth of -61.6% is below this long-term average.
How is PRME's revenue distributed by segment?
PRME reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2019-2025 are available for download. Segment mix reveals concentration and diversification trends.